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Clostridium difficile1,2  
Spore forming, anaerobic gram positive bacillus  
Spread via fecal-oral route 
Produces and releases toxins A and B 
Symptoms ranging from asymptomatic carrier, to diarrhea, to colitis, 
or to pseudomembranous colitis. 
Clostridium difficile infection (CDI) 
Rising concern in hospitals and long term care facilities due to 
patients being  prescribed antimicrobial(s) and exposure to organisms 
   
Exposure to broad-spectrum antibiotics1,2  
Exposure to the organism1,2 
Other risk factors: reduced gastric acid, immunosuppressive therapy, 
serious underlying illness and co-morbidities, gastrointestinal surgery, 
long duration of hospitalization, advanced age, etc. 1,2  
 
Antibiotic Stewardship1,2 
Hand hygiene and barrier precautions1,2 
Discontinue proton pump inhibitors (PPIs) to prevent CDI recurrence.3  
American Society of Health System Pharmacists (ASHP) Guidelines 4  
Recommends stress ulcer prophylaxis (SUP) with gastric acid 
suppressants for patients in the intensive care unit (ICU) meeting 
specific criteria 
SUP for adult patients in non-ICU settings are not recommended  
Probiotics may have moderate effectiveness in primary prevention of 
CDI.5 
 
The purpose of this study is to appropriately evaluate patients at risk of 
developing CDI, and to appropriately discontinue offending agents, if 
warranted, for patients identified as being high risk for developing CDI. 
Three month pilot study  from September 2015 to December 2015 
An electronic medical record system, Vigilanz™, provided daily reports 
scoring patients based on risk factors shown under Data Collection Sheet 
Patients with a score of three or higher were defined high risk 
High risk patients were reviewed by the pharmacist and appropriate CDI 
preventative recommendations were noted in the patient’s chart or via 
recommendations to attending physicians during multidisciplinary rounds 
Percentage of high risk patients on the floor 
Cases of hospital onset CDI 
Percentage of pharmacist interventions accepted 
Type and method of intervention accepted  
Percentage of inappropriate PPI use 
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